RNA-mediated mechanisms of motor system dysfunction in spinal muscular atrophy
RNA介导的脊髓性肌萎缩症运动系统功能障碍的机制
基本信息
- 批准号:10022699
- 负责人:
- 金额:$ 1.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-12-01 至 2020-02-29
- 项目状态:已结题
- 来源:
- 关键词:AddressAlternative SplicingAntisense OligonucleotidesBiogenesisBiologyCessation of lifeDataDefectDenervationDevelopmentDiseaseDisease modelEtiologyEventFunctional disorderGene DeliveryGene ExpressionGene TargetingGenesGeneticHistonesHumanIn VitroIndividualInfant MortalityInheritedKnowledgeLinkMediatingMessenger RNAMolecularMorphologyMotorMotor ManifestationsMotor Neuron DiseaseMotor NeuronsMusMutationNeurodegenerative DisordersNeuromuscular DiseasesNeuronsPathogenicityPathologyPathway interactionsPhenotypePlayPopulationPost-Transcriptional RegulationProcessRNARNA ProcessingRNA SplicingRegulationResearchResearch Project GrantsRoleSMN protein (spinal muscular atrophy)SMN1 geneSensorySmall Nuclear RibonucleoproteinsSpinal CordSpinal Muscular AtrophySpliced GenesSynapsesSynaptic TransmissionSystemSystems DevelopmentTP53 geneTestingTherapeuticU7 Small Nuclear RibonucleoproteinUp-RegulationVitelliform macular dystrophyWild Type Mousecell typedesigndisease phenotypein vivoinsightmRNA Precursormotor disordermotor neuron degenerationmouse modelneuromuscularneuron lossneurotransmissionpostnatalprotein functionrestorationskeletal muscle wastingtherapeutic developmenttranscriptometranscriptome sequencing
项目摘要
Project Summary
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized by
degeneration of motor neurons in the spinal cord and progressive atrophy of skeletal muscle. SMA is the most
frequent inherited cause of infant mortality and no treatment is currently available for the disease. SMA is
caused by a deficiency in the ubiquitously expressed survival motor neuron (SMN) protein due to homozygous
deletion or mutation of the SMN1 gene. Despite a clear genetic basis of the disease and progress in the
knowledge of SMN biology, the molecular mechanisms of SMA are poorly understood. SMN has a well-
established function in the biogenesis of small nuclear ribonucleoproteins (snRNPs) that are critical for RNA
splicing and 3' end formation of histone mRNAs. Moreover, it is becoming increasingly clear that SMN has
additional functions in RNA regulation that might also contribute to SMA. However, although SMN plays a
central role in post-transcriptional gene regulation, the contribution of specific SMN-dependent RNA pathways
to SMA pathology remains elusive. A major challenge in SMA research is to identify which SMN-dependent
RNA pathways and downstream genes among many potentially dysregulated events are directly relevant to
the disease phenotype. This is critically important to elucidate the molecular mechanisms of this devastating
disease and may also help to develop therapeutic approaches distinct from SMN upregulation. This project
aims to determine the direct contribution of three specific and well-established SMN-dependent RNA pathways
- U12 splicing, U7 snRNP biogenesis, and alternative splicing - to motor system dysfunction in a mouse model
of the disease that provides the best recapitulation of the human condition both genetically and phenotypically.
Our hypothesis is that specific defects in these pathways are causally linked to distinct functional abnormalities
of the SMA motor system. To address this hypothesis, we will investigate both the role of disruption of each of
these RNA pathways in SMA pathology and their requirement for normal motor system development using,
respectively, selective restoration (Aim 1) and inhibition (Aim 2) approaches in mouse models. These studies
will be combined with RNA profiling of select motor circuit neuron populations with the aim of identifying the
transcriptome alterations induced by SMN deficiency that are specifically associated with each RNA pathway
and their respective downstream gene targets that may directly contribute to the disease process, the
functional relevance of which will be tested in SMA mice (Aim 3). Collectively, this project is designed to
determine the RNA-dependent mechanisms of synaptic dysfunction and motor neuron death in SMA.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Livio Pellizzoni其他文献
Livio Pellizzoni的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Livio Pellizzoni', 18)}}的其他基金
Mechanisms and therapeutic targeting of motor neuron death in SMA
SMA 运动神经元死亡的机制和治疗靶向
- 批准号:
10334501 - 财政年份:2020
- 资助金额:
$ 1.74万 - 项目类别:
Mechanisms and therapeutic targeting of motor neuron death in SMA
SMA 运动神经元死亡的机制和治疗靶向
- 批准号:
10559530 - 财政年份:2020
- 资助金额:
$ 1.74万 - 项目类别:
Mechanisms and therapeutic targeting of motor neuron death in SMA
SMA 运动神经元死亡的机制和治疗靶向
- 批准号:
10087983 - 财政年份:2020
- 资助金额:
$ 1.74万 - 项目类别:
Essential role of Stasimon in motor circuit development and disease
Stasimon 在运动回路发育和疾病中的重要作用
- 批准号:
10312031 - 财政年份:2019
- 资助金额:
$ 1.74万 - 项目类别:
Essential role of Stasimon in motor circuit development and disease
Stasimon 在运动回路发育和疾病中的重要作用
- 批准号:
10531553 - 财政年份:2019
- 资助金额:
$ 1.74万 - 项目类别:
Essential role of Stasimon in motor circuit development and disease
Stasimon 在运动回路发育和疾病中的重要作用
- 批准号:
10057404 - 财政年份:2019
- 资助金额:
$ 1.74万 - 项目类别:
The Role of p38 MAPK Activation in Spinal Muscular Atrophy
p38 MAPK 激活在脊髓性肌萎缩症中的作用
- 批准号:
9317946 - 财政年份:2017
- 资助金额:
$ 1.74万 - 项目类别:
A genome-wide phenotypic screen for modifiers of SMN expression and function
SMN 表达和功能修饰因子的全基因组表型筛选
- 批准号:
8702410 - 财政年份:2014
- 资助金额:
$ 1.74万 - 项目类别:
相似海外基金
Alternative splicing of Grin1 controls NMDA receptor function in physiological and disease processes
Grin1 的选择性剪接控制生理和疾病过程中的 NMDA 受体功能
- 批准号:
488788 - 财政年份:2023
- 资助金额:
$ 1.74万 - 项目类别:
Operating Grants
RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing
RBFOX2 失调通过选择性剪接促进胰腺癌进展
- 批准号:
10638347 - 财政年份:2023
- 资助金额:
$ 1.74万 - 项目类别:
Long Noncoding RNA H19 Mediating Alternative Splicing in ALD Pathogenesis
长非编码 RNA H19 介导 ALD 发病机制中的选择性剪接
- 批准号:
10717440 - 财政年份:2023
- 资助金额:
$ 1.74万 - 项目类别:
Using proteogenomics to assess the functional impact of alternative splicing events in glioblastoma
使用蛋白质基因组学评估选择性剪接事件对胶质母细胞瘤的功能影响
- 批准号:
10577186 - 财政年份:2023
- 资助金额:
$ 1.74万 - 项目类别:
Alternative splicing regulation of CLTC in the heart
心脏中 CLTC 的选择性剪接调节
- 批准号:
10749474 - 财政年份:2023
- 资助金额:
$ 1.74万 - 项目类别:
Nitric oxide as a novel regulator of alternative splicing
一氧化氮作为选择性剪接的新型调节剂
- 批准号:
10673458 - 财政年份:2023
- 资助金额:
$ 1.74万 - 项目类别:
Alternative splicing as an evolutionary driver of phenotypic plasticity
选择性剪接作为表型可塑性的进化驱动力
- 批准号:
2884151 - 财政年份:2023
- 资助金额:
$ 1.74万 - 项目类别:
Studentship
Rescuing SYNGAP1 haploinsufficiency by redirecting alternative splicing
通过重定向选择性剪接挽救 SYNGAP1 单倍体不足
- 批准号:
10660668 - 财政年份:2023
- 资助金额:
$ 1.74万 - 项目类别:
CAREER: Mechanotransduction, transcription, and alternative splicing in cell biology
职业:细胞生物学中的机械转导、转录和选择性剪接
- 批准号:
2239056 - 财政年份:2023
- 资助金额:
$ 1.74万 - 项目类别:
Continuing Grant
Investigating the role of alternative splicing in the islets of Langerhans in developing diabetes.
研究朗格汉斯岛中选择性剪接在糖尿病发生中的作用。
- 批准号:
468851650 - 财政年份:2022
- 资助金额:
$ 1.74万 - 项目类别:
Research Grants